Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 364

1.

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y.

Int J Hematol. 2019 Apr;109(4):470-476. doi: 10.1007/s12185-019-02593-2. Epub 2019 Jan 25.

PMID:
30684252
2.

(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.

Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Grimaldi F, Zacheo I, Raimondo M, Sirignano C, Salvatore P, Pane F.

Ann Hematol. 2019 Feb;98(2):527-531. doi: 10.1007/s00277-018-3441-3. Epub 2018 Jul 23. No abstract available.

PMID:
30033485
3.

Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.

Seddon AN, Chaim J, Akin O, Drill E, Michael AG, Adel N, Tallman MS.

Leuk Res. 2018 May;68:48-50. doi: 10.1016/j.leukres.2018.03.004. Epub 2018 Mar 8.

PMID:
29544131
4.

Omics-Based Platform for Studying Chemical Toxicity Using Stem Cells.

Han Y, Zhao J, Huang R, Xia M, Wang D.

J Proteome Res. 2018 Jan 5;17(1):579-589. doi: 10.1021/acs.jproteome.7b00693. Epub 2017 Dec 20.

5.

Anthracycline-induced acute myocarditis and ventricular fibrillation arrest.

Pallazola VA, Murray JC, Al Harthy M, Zimmerman SL, Webster J, Gondek LP.

Am J Hematol. 2018 Mar;93(3):469-470. doi: 10.1002/ajh.24989. Epub 2017 Dec 18. No abstract available.

6.

Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice.

Attia SM, Alshahrani AY, Al-Hamamah MA, Attia MM, Saquib Q, Ahmad SF, Ansari MA, Nadeem A, Bakheet SA.

Toxicol Sci. 2017 Nov 1;160(1):161-172. doi: 10.1093/toxsci/kfx161.

PMID:
28973540
7.

Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).

Shao H, Yang Q, Wu C, Cen J, Chen S, Pan J.

Ann Hematol. 2017 Dec;96(12):2127-2129. doi: 10.1007/s00277-017-3110-y. Epub 2017 Aug 24. No abstract available.

PMID:
28840298
8.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H.

Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub 2017 Jul 14.

9.

Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.

Brierley CK, Eyre TA.

Blood. 2017 Jun 22;129(25):3396. doi: 10.1182/blood-2017-03-765776. No abstract available.

10.

Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.

Rodríguez-Veiga R, Igual B, Montesinos P, Tormo M, Sayas MJ, Linares M, Fernández JM, Salvador A, Maceira-González A, Estornell J, Calabuig M, Pedreño M, Roig M, Sanz J, Sanz G, Carretero C, Boluda B, Martínez-Cuadrón D, Sanz MÁ; spanish PETHEMA group.

Ann Hematol. 2017 Jul;96(7):1077-1084. doi: 10.1007/s00277-017-3004-z. Epub 2017 Apr 28.

PMID:
28451804
11.

Escalated anthracycline dose in adult AML.

Balakrishnan VS.

Lancet Oncol. 2017 May;18(5):e253. doi: 10.1016/S1470-2045(17)30277-2. Epub 2017 Apr 13. No abstract available.

PMID:
28416149
12.

Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia.

Tsunaka M, Shinki H, Koyama T.

PLoS One. 2017 Apr 13;12(4):e0175765. doi: 10.1371/journal.pone.0175765. eCollection 2017.

13.

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.

Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, Scheffers L, Hasle H, Zwaan CM, Reinhardt D, Klusmann JH.

Blood. 2017 Jun 22;129(25):3314-3321. doi: 10.1182/blood-2017-01-765057. Epub 2017 Apr 11.

14.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
15.

Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.

Woelich SK, Braun JT, Schoen MW, Ramlal R, Freter CE, Petruska PJ, Lionberger JM.

Anticancer Res. 2017 Feb;37(2):713-717.

PMID:
28179321
16.

Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.

Tang YL, Chia WK, Yap EC, Julia MI, Leong CF, Salwati S, Wong CL.

Malays J Pathol. 2016 Dec;38(3):315-319.

17.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H.

Cancer. 2017 Feb 1;123(3):426-435. doi: 10.1002/cncr.30361. Epub 2016 Sep 22.

18.

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.

Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F.

BMJ Open. 2016 Jun 24;6(6):e010696. doi: 10.1136/bmjopen-2015-010696.

19.

sQuiz your knowledge: Generalized lesions resembling water droplets after treatment with idarubicin and all-trans retinoic acid.

Arjona-Aguilera C, Rodríguez CC, Jiménez-Gallo D.

Eur J Dermatol. 2016 Jun 1;26(3):329-31. doi: 10.1684/ejd.2016.2816. No abstract available.

PMID:
27328664
20.

Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.

Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R.

Med Mal Infect. 2016 Jun;46(4):226-9. doi: 10.1016/j.medmal.2016.03.008. Epub 2016 Apr 25.

PMID:
27126350

Supplemental Content

Loading ...
Support Center